Health Condition 1: null- All patients presenting with chronic urticaria aged above 18 years and symptoms not relieved by single daily dose of tab. levocetirizine 5mg for 2 weeks.
Conditions
Interventions
Intervention1: levocetirizine 10mg: levocetirizine 10mg will be given for 4 weeks daily at night
Control Intervention1: levocetirizine 5mg with montelukast 10 mg: levocetirizine 5mg with montelukast 1
Sponsors
Medical College Kolkata
Eligibility
Inclusion criteria
Inclusion criteria: All patients presenting with chronic urticaria aged above 18 years and symptoms not responding to a single daily dose of second generation antihistamine (levocetirizine 5mg once daily dose) even after 2 weeks of therapy.
Exclusion criteria
Exclusion criteria: 1.Pregnant and lactating females. 2.Patients having immunosuppression due to drug or disease. 3.Patients having end stage renal disease. 4.Patients allergic to levocetirizine, cetrizine or its parent compound hydroxyzine, montelukast. 5.Patients not consenting.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A.To assess the clinical effectiveness of montelukast 10 mg and levocetirizine 5 mg versus levocetirizine 10 mg in cases of CU not responding to 5mg levocetirizine. 1. By urticaria severity score(uss) 2. By total severity score(tss) B.To compare the safety of the two treatments. 1. By laboratory method 2. By checklist the adverse effectsTimepoint: A. Baseline and End of 1st wk, 2nd wk, 3rd wk &4th wk B. 1.Baseline and post treatment value | — |
Secondary
| Measure | Time frame |
|---|---|
| A.To estimate the cost of therapy of the two groups. B.To compare the quality of life in both the treatment arms. Timepoint: Baseline and end of 4th week. | — |
Countries
India
Contacts
Public ContactDr Amrita Sil
Medical College Hospital
Outcome results
None listed